Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain (CAPSONCO)
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
This PHASE2 trial investigates Neuropathic Pain and is currently completed. Centre Hospitalier Universitaire de Saint Etienne leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
May 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Saint Etienne
- Institut de Cancérologie de la Loire
For direct contact, visit the study record on ClinicalTrials.gov .